The 6th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization.

The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.

View flyer here for our outstanding selected speakers and members of the Steering Committee.

The 6th Global Summit will build on the success of the previous Global Summits, which have emerged as the seminal events in recognizing the importance of a comprehensive, multimodality diagnostic evaluation (radiogenomics) and its integration with clinical decisions, including appropriate interventions and management. To learn more about the Annual Summit history and highlights, please visit here 


The scope of the Summit includes a full spectrum of patient care cycle:

  • Current and future advances in “smart screening”;
  • Diagnostic assessment of men suspected of prostate cancer (PC);
  • Selection of patients for biopsies and improved tissue sampling;
  • Improved diagnosis of localized PC and selection of patients for appropriate care (e.g., AS, image-targeted, minimally invasive interventions, or immediate standard treatment, such as radical surgery or radiation);
  • Improved early diagnosis of recurrent and advanced PC, including oligometastatic and systemic metastatic disease;
  • Expanded discussion on image-guided, minimally-invasive treatment and its clinical utility in localized, recurrent and advanced disease compared to other therapeutic interventions; and
  • Increased participation of the organizations leading training, accreditation, regulatory and reimbursement policies to expedite clinical evaluation and adoption of promising novel diagnostics and therapeutics.

We would welcome sponsorship of the 5th Global Summit on Precision Diagnosis and Treatment for Prostate Cancer. Please review Sponsorship Levels and Sponsorship Registration Form.

If you have any questions and/or need more information regarding the planned Summit program or sponsorship, please contact our office by email ( or phone 617-523-3535.

Previous Summits




Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit and follow Telix on Twitter (@TelixPharma) and LinkedIn


At Amgen Oncology, our mission to serve patients drives all that we do. That’s why we’re relentlessly focused on accelerating the delivery of medicines that have the potential to empower all angles of care and transform the lives of people with cancer.

For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the Company’s history, moving with great speed to advance those innovations for the patients who need them.

At Amgen, we’re advancing oncology at the speed of life.

For more information, follow us on

Driven by purpose

At Philips, our purpose is to improve people’s health and well-being through meaningful innovation. We aim to improve 2.5 billion lives per year by 2030, including 400 million in underserved communities.

As a technology company, we – and our brand licensees – innovate for people with one consistent belief: there’s always a way to make life better.


Blue Earth Diagnostics, a subsidiary of Bracco Imaging, is a recognized leader in the development and commercialization of novel PET radio-pharmaceuticals to inform clinical management for cancer patients. Its portfolio includes a commercial product for recurrent prostate cancer and a robust pipeline of investigational agents. For more information, visit:

Exosome Diagnostics, a Bio-Techne brand, is based outside of Boston, MA with a mission focused on developing and commercializing revolutionary, exosome-based diagnostics to deliver personalized precision healthcare that improves lives.

Our liquid biomarker, ExoDx™ Prostate (IntelliScore), or EPI, is a simple urine test that delivers unique, actionable intelligence to help with the prostate biopsy decision. The EPI score is a standalone test, and not influenced by standard of care or common clinical features such as DRE, family history, or PSA level. Clinical studies demonstrate that the EPI Test improves patient compliance and identifies more high- grade prostate cancers (HGPCa) compared to standard of care alone. EPI is also telemedicine enabled with its At-Home Collection Kit for patients who cannot travel long distances to see their provider.

The ExoDx Prostate Test has been included in the National Comprehensive Cancer Network guidelines (NCCN guidelines) for early detection of prostate cancer since 2019, is covered by Medicare and several private commercial payors, and covered for U.S. Veterans under the General Services Administration (GSA) award.


Lantheus is an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to Find Fight and Follow® serious medical conditions.

For more information, please visit

At Siemens Healthineers, we pioneer breakthroughs in healthcare. For everyone. Everywhere. By constantly bringing breakthrough innovations to market, we enable healthcare professionals to deliver high-quality care, leading to the best possible outcome for patients.

Our portfolio, spanning from in-vitro and in-vivo diagnostics to image-guided therapy and innovative cancer care, is crucial for clinical decision-making and treatment pathways. With our strengths in patient twinning, precision therapy, as well as digital, data, and artificial intelligence (AI), we are well positioned to take on the biggest challenges in healthcare. We will continue to build on these strengths to help fight the world’s most threatening diseases, improving the quality of outcomes, and enabling access to care.

We are a team of 66,000 highly dedicated employees across more than 70 countries passionately pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.


Advanced Accelerator Applications (AAA), a Novartis company, is a medicines company developing targeted RLT and imaging radioligands in oncology. We are committed to transforming patients’ lives by leading innovation in nuclear medicine.

To learn more please visit

Focal One® Robotic HIFU is the first and only robotic platform designed for focal ablation of prostate tissue using High Intensity Focused Ultrasound that is controlled by the urologist.

ExactVu™ Micro-Ultrasound Targeted Biopsies is the world’s first and only targeted biopsy system using 29 MHz Micro-Ultrasound technology providing 300% improved resolution over traditional ultrasound.

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at

Profound Medical develops customizable, incision-free therapies which combine real-time Magnetic Resonance (“MR”) imaging, thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue.

Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. We believe TULSA-PRO® is demonstrating to be a flexible technology in customizable prostate ablation, including intermediate-stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (BPH).


Avenda Health is creating a more personalized future of prostate cancer care.  Using deep learning, Avenda Health software maps a patient’s cancer in 3D, giving physicians precise information and the confidence to make care decisions.  Dedicated to bringing this cutting-edge technology to all practices and physicians treating prostate cancer patients, Avenda Health aims to improve outcomes, preserve quality of life, and create a new standard of cancer care.

To learn more visit us at

Canon Medical Systems USA delivers innovative imaging solutions and services through our Made for Life philosophy to improve the quality of life for all people.

To learn more, please visit:

OPKO Health, Inc., provider of the 4Kscore® Test, is uniquely positioned with a comprehensive test menu to meet all your laboratory testing needs for urology patient diagnosis and management. 4Kscore is a blood test used to detect the risk of aggressive prostate cancer after an abnormal PSA or DRE result.  Urologists can order 4Kscore to help make a decision on whether a biopsy is appropriate and also to evaluate patient results & discuss next steps.

To learn more, please visit:

MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of prostate cancer and other urologic diseases. The company’s tests are based on proprietary genetic, epigenetic, and other complex molecular technologies.

MDxHealth is dedicated to providing highly accurate and clinically actionable urologic solutions to inform patient diagnosis and treatment while improving healthcare economics for payers and providers.

Veru Inc. is an Oncology Biopharmaceutical Company Focused on Breast Cancer and Prostate Cancer.

To learn more, please visit:


The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested nearly $1 trillion in the search for new treatments and cures.

To learn more, please visit